CG Oncology, Inc. (CGON)
NASDAQ: CGON · IEX Real-Time Price · USD
31.32
-0.40 (-1.26%)
At close: Jul 2, 2024, 4:00 PM
32.02
+0.70 (2.23%)
After-hours: Jul 2, 2024, 7:13 PM EDT
CG Oncology Revenue
Revenue in the quarter ending March 31, 2024 was $529.00K. In the year 2023, CG Oncology had annual revenue of $204.00K with 6.81% growth.
Revenue (ttm)
$204.00K
Revenue Growth
+6.81%
P/S Ratio
3,872.30
Revenue / Employee
$8,836
Employees
61
Market Cap
2.09B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 204.00K | 13.00K | 6.81% |
Dec 31, 2022 | 191.00K | -10.17M | -98.16% |
Dec 31, 2021 | 10.36M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCGON News
- 26 days ago - CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC - GlobeNewsWire
- 5 weeks ago - CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting - GlobeNewsWire
- 7 weeks ago - CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 2 months ago - CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 - GlobeNewsWire
- 2 months ago - CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024 - GlobeNewsWire
- 3 months ago - CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting - GlobeNewsWire
- 5 months ago - CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - Business Wire